Eight Chinese Biopharma Companies Secure Over RMB 100 Million in Funding Last Month and File IPO Prospectuses

　　【Pharmaceuticals Network Industry Dynamics】Looking back at July, how was the investment and financing situation in China's pharmaceuticals sector? According to the summary, in July this year, 15 domestic biopharmaceutical enterprises completed a new round of financing. Among them, eight pharmaceutical companies raised over 100 million RMB, including Novamab, Zetane Biologics, ReviR Therapeutics, BAO PHARMA, Rona Therapeutics, AusperBio, Maitai Biotechnology, and Guangzhou Colony Biotechnology Co., Ltd.
 

Novamab Successfully Completed Nearly 200 Million RMB B2 Financing Last Month. The Funds Raised in This Round Will Mainly Be Used to Advance the Phase II Clinical Studies of Two Inhaled Antibody Drugs (LQ036, LQ043H) Independently Developed by the Company Based on the "Inhaled Large Molecule Drug Development Platform," While Enriching the Company’s Pipeline in the Autoimmune Field, Strengthening the Team, and Further Supplementing Corporate Working Capital.
 

Data shows that Novamab is a biotechnology company dedicated to the research and development of innovative nanobody drugs. It has now established a complete R&D, CMC, and pilot production system, and built five major innovative technology platforms, taking an early lead in pioneering the research of fast-acting, highly specific inhaled nanobodies.
 

Zean Bio last month completed an A-round financing of over 20 million US dollars. The newly raised funds will mainly be used to accelerate the development of the LTZ pipeline, including filing for Investigational New Drug (IND) applications, initiating Phase I clinical trials for LTZ-301 and IND-enabling work for LTZ-232, rapidly advancing other ongoing projects, etc.; additionally, it will be used to further expand the global team.
 

Data shows that Zeanon Biopharmaceuticals is a biotechnology company focused on immunotherapy, dedicated to developing new therapies to improve clinical outcomes for cancer and other diseases with unmet clinical needs. The company is developing its own novel innate engagement platform, a broad-spectrum multifunctional antibody platform targeting natural immune cells.
 

ReviR Therapeutics Completed $30 Million Series A Financing Last Month to Accelerate the Development of RNA-Targeted Small Molecule Drugs
 

BAO PHARMA Completes CNY Hundreds of Millions in Series C Financing, to Further Advance and Commercialize Synthetic Biology Technology PlatformBAO PHARMA, a pharmaceutical company integrating R&D, production, and sales in the field of synthetic biology-based biomedicine, will mainly use the funds to drive the further development and commercialization of its synthetic biology technology platform. The company focuses on the "synthetic biology" technology platform to develop recombinant drugs that are difficult to express through conventional genetic engineering.
 

Rona Therapeutics Completes $35 Million Series A+ Financing. Rona Therapeutics is a company focused on the research and development of nucleic acid drugs, dedicated to studying, developing, and producing nucleic acid drugs for diseases in metabolic, central nervous system, ophthalmology, oncology, and other fields. This round of financing will mainly be used to support Rona Therapeutics' further exploration and expansion in the field of nucleic acid drug development, advance the company’s product R&D progress, and provide financial backing for future commercialization plans.
 

AusperBio Completes $37 Million Series A Financing. The proceeds from this round will be mainly used to rapidly advance the Phase II clinical trial of AusperBio's potential cornerstone drug for hepatitis B cure, AHB-137, exploration of combination therapy regimens, CMC production, and a series of other development activities. Meanwhile, the funds will also be utilized to expand the proprietary Med-Oligo™ technology platform and its product pipeline.
 

Maikang Bio Obtains Over 300 Million Yuan in C+ Round Financing: Funds Will Mainly Support Phase III Clinical Trials for Recombinant Shingles Vaccine, Phase I and II Clinical Studies for Recombinant Respiratory Syncytial Virus Vaccine, and Preclinical R&D and International Collaboration for Multiple Innovative Vaccine Pipelines.
 

Guangzhou Colony Biotechnology Co., Ltd. Completes CNY 300 Million C+ Round Financing. Guangzhou Colony Biotechnology Co., Ltd., a platform-based biotechnology company specializing in microbial discovery and bio-manufacturing, has established a complete industrial technology system for discovering, screening, modifying, and applying microorganisms, as well as building microbial strain and genetic component libraries. The new round of funding will mainly be used to advance the scaled production and commercialization of more bio-innovative products, expand its proprietary commercial microbial strain and component libraries, and further enhance its bio-manufacturing technology platform.
 

Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute investment advice to any person.